

Chapman University

## Chapman University Digital Commons

---

Biology, Chemistry, and Environmental Sciences Faculty Articles and Research      Science and Technology Faculty Articles and Research

---

8-8-2017

# Carbonyl Reduction by YmfI Completes the Modification of EF-P in *Bacillus subtilis* to Prevent Accumulation of an Inhibitory Modification State

Katherine R. Hummels  
*Indiana University - Bloomington*


Anne Witzky  
*The Ohio State University*

Andrei Rajkovic  
*The Ohio State University*

Rodney Tollerson II  
*The Ohio State University*

Lisa A. Jones  
*Fred Hutchinson Cancer Research Center*

Follow this and additional works at: [https://digitalcommons.chapman.edu/sees\\_articles](https://digitalcommons.chapman.edu/sees_articles)

 [next page for additional authors](#)  
Part of the [Amino Acids, Peptides, and Proteins Commons](#), [Biochemistry Commons](#), [Cellular and Molecular Physiology Commons](#), [Molecular Biology Commons](#), [Nucleic Acids, Nucleotides, and Nucleosides Commons](#), and the [Other Biochemistry, Biophysics, and Structural Biology Commons](#)

---

### Recommended Citation

Hummels, K.R., Witzky, A., Rajkovic, A., Tollerson, R., Jones, L.A., Ibba M. and Kearns, D.B. (2017) Carbonyl reduction by YmfI completes the modification of EF-P in *Bacillus subtilis* to prevent accumulation of an inhibitory modification state. *Mol. Microbiol.* **106**, 236-251. <https://doi.org/10.1111/mmi.13760>

This Article is brought to you for free and open access by the Science and Technology Faculty Articles and Research at Chapman University Digital Commons. It has been accepted for inclusion in Biology, Chemistry, and Environmental Sciences Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information, please contact [laughtin@chapman.edu](mailto:laughtin@chapman.edu).

---

## Carbonyl Reduction by YmfI Completes the Modification of EF-P in *Bacillus subtilis* to Prevent Accumulation of an Inhibitory Modification State

### Comments

This is the accepted version of the following article:

Hummels, K.R., Witzky, A., Rajkovic, A., Tollerson, R., Jones, L.A., Ibba M. and Kearns, D.B. (2017) Carbonyl reduction by YmfI completes the modification of EF-P in *Bacillus subtilis* to prevent accumulation of an inhibitory modification state. *Mol. Microbiol.* **106**, 236-251.

which has been published in final form at <https://doi.org/10.1111/mmi.13760>. This article may be used for non-commercial purposes in accordance with [Wiley Terms and Conditions for Self-Archiving](#).

### Copyright

Wiley

### Authors

Katherine R. Hummels, Anne Witzky, Andrei Rajkovic, Rodney Tollerson II, Lisa A. Jones, Michael Ibba, and Daniel B. Kearns



Published in final edited form as:

*Mol Microbiol.* 2017 October ; 106(2): 236–251. doi:10.1111/mmi.13760.

## Carbonyl reduction by YmfI in *Bacillus subtilis* prevents accumulation of an inhibitory EF-P modification state

Katherine R. Hummels<sup>1</sup>, Anne Witzky<sup>2</sup>, Andrei Rajkovic<sup>3</sup>, Rodney Tollerson II<sup>3</sup>, Lisa A. Jones<sup>4</sup>, Michael Ibba<sup>3</sup>, and Daniel B. Kearns<sup>1,\*</sup>

<sup>1</sup>Department of Biology, Indiana University, Bloomington, Indiana 47405

<sup>2</sup>Department of Molecular Genetics and Center for RNA Biology, Ohio State University, Columbus, Ohio 43210

<sup>3</sup>Department of Microbiology and Center for RNA Biology, Ohio State University, Columbus, Ohio 43210

<sup>4</sup>Proteomics Facility, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109

### Abstract

Translation elongation factor P (EF-P) in *Bacillus subtilis* is required for a form of surface migration called swarming motility. Furthermore, *B. subtilis* EF-P is post-translationally modified with a 5-aminopentanol group but the pathway necessary for the synthesis and ligation of the modification is unknown. Here we determine that the protein YmfI catalyzes the reduction of EF-P-5 aminopentanone to EF-P-5 aminopentanol. In the absence of YmfI, accumulation of 5-aminopentanonylated EF-P is inhibitory to swarming motility. Suppressor mutations that enhanced swarming in the absence of YmfI were found at two positions on EF-P, including one that changed the conserved modification site (Lys 32) and abolished post-translational modification. Thus, while modification of EF-P is thought to be essential for EF-P activity, here we show that in some cases it can be dispensable. YmfI is the first protein identified in the pathway leading to EF-P modification in *B. subtilis*, and *B. subtilis* encodes the first EF-P ortholog that retains function in the absence of modification.

### Keywords

YmfI; EF-P; translation; post-translational modification; swarming motility

## INTRODUCTION

The protein Elongation Factor P (EF-P) is a translation elongation factor highly conserved in all living things (eIF-5a in Eukaryotes and aIF-5a in Archaea) (Ganoza, 2002, Lassak, 2016, and Rajkovic, 2017). Recent work has shown that EF-P enhances translation of particular codon combinations encoding prolines in both Bacteria and Eukaryotes (Doerfel, 2013, Ude, 2013, and Gutierrez, 2013). The mechanism by which EF-P potentiates translation is poorly

\*corresponding author: dbkearns@indiana.edu, 1-812-856-2523.

understood but EF-P structurally resembles a tRNA molecule, has been shown to bind between the E and P sites of the ribosome, and may function catalytically by increasing entropy (Blaha, 2009, Hanawa-Suetsugu, 2004, Doerfel, 2015 and Schmidt, 2016). In nearly all systems studied to date, depletion of EF-P is either lethal or results in severe growth limitation, presumably due to the impaired ability to translate target sequences in essential genes (Balibar, 2013, Patel, 2009, Schnier, 1991, and Yanagisawa, 2016). The one exception thus far is the Gram positive firmicute bacterium *Bacillus subtilis* where EF-P is not required for growth and is instead specifically required for swarming motility, a flagellar-mediated multicellular behavior in which cells rapidly move across a semi-solid surface (Kearns, 2004; Rajkovic, 2016).

In all organisms tested to date, EF-P is post-translationally modified on a conserved lysine/arginine residue at a position analogous to the amino acid acceptor site of tRNAs (Katz, 2013). The chemical nature of the EF-P post-translational modification varies between species. Within the proteobacteria, *Escherichia coli* and *Salmonella enterica* modify EF-P lysine 34 with a  $\beta$ -lysine group (Blaha, 2010 and Navarre, 2010), whereas *Neisseria meningitidis*, *Pseudomonas aeruginosa* and *Shewanella oneidensis* modify EF-P arginine 32 with a rhamnose moiety (Lassak, 2015, Rajkovic, 2015, and Yanagisawa, 2016). The EF-P ortholog in Eukaryotes, eIF5A, is modified by the addition of hypusine (Cooper, 1983). In each case mentioned thus far the function of the modification is thought to be essential for EF-P activity because mutations in the modification system result in growth defects similar to *efp* deletion mutants and reduce the translation rate of consecutive prolines (Patel, 2009, Sasaki, 1996, Yanagisawa, 2009, Doerfel et al., 2013, and Yanagisawa, 2015). The mechanism by which the various modification groups enhance EF-P activity is unknown.

*B. subtilis* modifies EF-P lysine 32 with yet another chemical variant, 5-aminopentanol. Substitution of the conserved modified lysine to alanine (EF-P<sup>K32A</sup>) was shown to impair surface motility but the enzymes required for 5-aminopentanylation were unknown (Rajkovic, 2016). Here, we revisit the swarming mutants from the same screen that first discovered EF-P as a swarming motility activator and we identify YmfI as a protein required for EF-P 5-aminopentanylation. YmfI is paralogous to the fatty acid biosynthesis gene FabG and catalyzes the reduction of 5-aminopentanone to 5-aminopentanol as, in the absence of YmfI, EF-P was modified with a 5-aminopentanone group and cells exhibit attenuated swarming motility. Finally, in a forward genetic screen, we identify mutations in *efp* that bypass the requirement for YmfI in swarming motility and in one of the mutants, EF-P<sup>K32R</sup>, post-translational modification was abolished. Thus, YmfI is the first example of an enzyme involved in EF-P modification in *B. subtilis*, and the *B. subtilis* EF-P is the first example that retains activity in the absence of modification.

## RESULTS

### The absence of YmfI impairs swarming motility

EF-P proteins are thought to be activated by post-translational modification and *B. subtilis* EF-P is post-translationally modified by a 5-aminopentanol group attached to lysine 32 (Rajkovic, 2016). *B. subtilis* EF-P resolved as two bands in semi-native gel electrophoresis and Western blot analysis, and we hypothesized that the two bands could represent different

states of EF-P modification and/or activity (Fig 1A left, lane T<sub>0</sub>). To determine whether the two species of EF-P were differentiated by a post-translational mechanism, translation was inhibited by the addition of spectinomycin and EF-P electrophoretic mobility in semi-native gel electrophoresis was monitored over time. Within 15 minutes of inhibiting translation, the lower band species of EF-P diminished in abundance (Fig 1A left, lanes T<sub>0</sub>-T<sub>240</sub>). We hypothesize that the two bands of EF-P represent different post-translational modification states.

To find proteins involved in EF-P post-translational modification, whole cell lysates of transposon mutants taken from the same screen that identified the swarming motility defect of an *efp* mutant were resolved by semi-native gel electrophoresis and Western blot analysis (Kearns and Losick, 2004). Mutation of one gene, *ymfI*, resulted in a single species of EF-P (Fig 1B). When resolved side-by-side, EF-P of the *ymfI* mutant exhibited an electrophoretic mobility similar to the lower band found in the wild type (Fig 1C, compare lanes 1 and 2). Moreover, the band intensity of *ymfI*EF-P did not change over time after spectinomycin treatment (Fig 1A middle). We conclude that the protein encoded by the *ymfI* gene, YmfI, alters EF-P mobility in semi-native gels and we hypothesize that YmfI might control EF-P post-translational modification.

Whereas mutation of *efp* results in a severe defect in swarming motility, mutation of *ymfI* resulted in periodic cessation and reinitiation of swarming motility to create a terraced colony appearance on swarm plates (Fig 2A,B) (Kearns and Losick, 2004). The terracing pattern of swarming was reminiscent of an EF-P mutant defective in post-translation modification in which the modification site lysine 32 was mutated to an alanine (Fig 2A,C) (Rajkovic et al., 2016). In both qualitative and quantitative analyses, the swarming defect of the *efp*<sup>K32A</sup> mutant was more severe than that of a *ymfI* mutant (Fig 2A,C). Furthermore, the swarming motility of a *ymfI efp*<sup>K32A</sup> double mutant resembled that of the *efp*<sup>K32A</sup> mutant alone, suggesting that the *efp*<sup>K32A</sup> mutation was epistatic (Fig 2A,C). As further evidence of epistasis, Western blots of EF-P resolved by semi-native gel electrophoresis indicated an altered mobility of the mutant EF-P<sup>K32A</sup> protein that was not further altered by the absence of YmfI (Fig 1C, compare lanes 3 and 4). We conclude that YmfI requires EF-P lysine residue 32 to promote swarming motility and alter EF-P electrophoretic mobility.

YmfI is homologous to FabG, a 3-keto-acyl ACP reductase essential for fatty acid biosynthesis in *E. coli*, and contains conserved active site residues (Fig S1A) (Price, 2001). Whereas FabG is essential for growth, cells mutated for *ymfI* exhibited only a 5% decrease in growth rate resembling the slight growth rate reduction found in cells mutated for *efp* (Fig S2). To determine whether the YmfI active site residues are required for promoting swarming motility and altering EF-P semi-native gel mobility, we first complemented the *ymfI* mutation *in trans*. The *ymfI* gene appeared to be the third gene in a putative four gene operon (*ymfFHIJ*) (Fig 3A), and swarming motility was restored to the *ymfI* mutant when *ymfI* was cloned downstream of the *P<sub>ymfF</sub>* promoter and inserted at an ectopic site in the chromosome (*amyE::P<sub>ymfF</sub>-ymfI*) (Fig 2D). Thus, the *ymfI* mutant defect was due to the absence of *ymfI*, not due to a polar effect on other genes in the operon which, when mutated, had no effect on swarming motility or EF-P native gel electrophoretic mobility (Fig S3A-E). The ectopic *ymfI* complementation construct did not restore swarming motility to the *ymfI*

mutant, however, when the *ymfI* putative active site residue tyrosine 150 was mutated to an alanine (*amyE::P<sub>ymfI</sub>-ymfI<sup>Y150A</sup>*) (Fig 2D, Fig S1A). We conclude that the active site residue of YmfI is required for either YmfI activity or stability and we infer that YmfI may activate EF-P enzymatically.

To determine if YmfI directly participates in the alteration of EF-P electrophoretic mobility, recombinant YmfI was purified from *E. coli* and EF-P-FLAG was purified from the *B. subtilis ymfI* mutant (EF-P-FLAG<sup>*ymfI*</sup>). EF-P-FLAG<sup>*ymfI*</sup> resolved as a single band on semi-native gel electrophoresis in the absence of YmfI or in the presence of YmfI but the absence of NADPH (Fig 1D, left and middle lanes). Upon incubation of EF-P-FLAG<sup>*ymfI*</sup> in the presence of both purified YmfI and NADPH, however, a faint upper band resolved on semi-native gel electrophoresis (Fig 1D, right lane). We conclude that YmfI is an enzyme that requires the NADPH cofactor and is sufficient *in vitro* to alter EF-P electrophoretic mobility on a semi-native gel.

### YmfI is required for 5-aminopentanoylation of EF-P

One way in which YmfI might alter semi-native gel electrophoretic mobility in a manner dependent on its enzymatic activity is if YmfI is involved in 5-aminopentanoylation of EF-P. In order to assess the modification status of EF-P, EF-P was affinity tagged and ectopically overexpressed from an IPTG-inducible promoter in *efp* and *efp ymfI* mutant backgrounds and subjected to chymotrypsin in-gel digestion. The digested protein was then resolved on an orbitrap elite mass spectrometer, and subjected to electron transfer dissociation fragmentation to generate a complete MS2 spectrum of the peptide containing Lys32 (QHVKPGKGAAF). In the wild type, both unmodified (Fig 4A, 1138.624 Da) and 5-aminopentanoylated (Fig 4B, 1239.709 Da) EF-P peptides were detected. The additional mass of 101.085 Da is consistent with previous reports for 5-aminopentanol C<sub>5</sub>H<sub>12</sub>NO (Rajkovic et al., 2016). In the absence of YmfI, unmodified peptides were detected but instead of a 101.085 Da mass, a mass of 99.068 Da was identified on Lys32 (Fig 5). From the mass difference of 2 Da we determined that in the absence of YmfI, the post-translational modification on Lys32 is C<sub>5</sub>H<sub>10</sub>NO. Although C<sub>5</sub>H<sub>10</sub>NO could represent multiple different structures, based on previous MS3 data of 5-aminopentanol and the proposed reductase activity of *ymfI*, we suggest it likely corresponds to 5-aminopentanone (Fig 4F). Further, while the precise position of the carbonyl can only be unequivocally determined with the use NMR or other high resolution structural methods, we suggest it likely corresponds to the position of the hydroxyl group in 5-aminopentanol at either the C<sub>3</sub> or C<sub>4</sub> position (Rajkovic 2016).

Very low levels of 5-aminopentanoylated EF-P also appeared to be detected in the absence of *ymfI* (Fig 4E). As the reduced and oxidized forms differ by two hydrogen atoms, however, it is possible that the parent ion predicted to be the 5-aminopentanoylated peptide is in reality a heavy isotope of the 5-aminopentanone peptide. In order to address this possibility, a predicted isotope distribution was calculated for QHVKPGKGAAF with either modification, and compared to the measured isotope distribution (Fig S4). Actual measured abundances for each isotope of the 5-aminopentanone peptide in the *ymfI* background corresponded with predicted abundances precisely, but not for the 5-aminopentanoylated

peptide. Thus, the apparent 5-aminopentanolylated peptide in the *ymfI* mutant is likely an artifact of heavy isotope incorporation. Although the possibility that extremely low levels of 5-aminopentanol exist in the absence of *ymfI* cannot be ruled out, the differences between the predicted and actual isotope distribution for 5-aminopentanolylated EF-P makes this possibility remote. We conclude that YmfI is an enzyme that directly catalyzes the reduction of 5-aminopentanone to 5-aminopentanol. We further conclude, based on YmfI's ability to alter EF-P electrophoretic mobility *in vitro*, that YmfI alone is capable of catalyzing the reduction reaction when the substrate is ligated to EF-P.

During the mass spectrometry analyses, we noted that there appeared to be a relative excess of unmodified EF-P that did not seem consistent with the relative band intensity in the wild type (Compare Fig 1A left and Fig 4A,B). As the EF-P-FLAG construct was expressed from an IPTG-inducible promoter, we wondered whether 1 mM IPTG induction was causing over-representation of the unmodified form. Thus, an IPTG-titration was conducted for both the swarming motility phenotype and the semi-native gel Western blots. The *P<sub>hyspank</sub>-efp-FLAG* construct restored swarming motility to the *efp* mutant even in the absence of IPTG, suggesting that leakiness of the promoter was sufficient to rescue the phenotype (Fig 6A, upper) though EF-P protein was not detectable by Western blot analysis until 0.01 mM IPTG was added (Fig 6A, lower). Moreover, the EF-P upper band saturated in intensity while the lower band continued to accumulate (Fig 6A, lower). We conclude that the affinity-tagged version of EF-P is functional at very low levels in the *efp* mutant and that IPTG-induction resulted in hyper-accumulation of the unmodified form. In the *efp ymfI* double mutant, however, 0.03 mM IPTG induction of EF-P-FLAG was required to restore partial swarming (Compare first four lanes of Fig 6A,B upper). Further, 0.05 mM IPTG and greater allowed the *efp ymfI* double mutant to swarm at a faster rate than the *ymfI* mutant alone (Fig 6B, upper). Regardless, in the absence of YmfI, only one EF-P band was detected in Western blot analysis at all IPTG concentrations tested (Fig 6B, lower). We conclude that the *efp ymfI* double mutant requires more EF-P for swarming motility and that EF-P overexpression could partially suppress the absence of YmfI.

### Modification independent alleles of EF-P bypass the need for YmfI

To explain the swarming defect of the *ymfI* mutant, we hypothesized that either the reduced 5-aminopentanol modification was essential for EF-P activity, or the oxidized 5-aminopentanone modification was inhibitory. To distinguish the two possibilities, we randomly mutagenized the *efp* gene and screened for mutations that bypass the need for YmfI. If the 5-aminopentanol group was essential for activity, we predicted that there would be no mutation in *efp* sufficient to bypass the absence of YmfI. To set up the screen, we first complemented the *efp* mutation *in trans*. The *efp* gene appears to be the third gene in a putative three gene operon (*yqhS-papA-efp*) (Fig S3F), and swarming motility was restored to the *efp* mutant when *efp* was cloned downstream of the *P<sub>yqhS</sub>* promoter region and inserted at an ectopic site in the chromosome (*amyE::P<sub>yqhS</sub>-efp*) (Fig 2E). Thus the *efp* mutant defect was due to the absence of EF-P, not due to a polar effect on other genes in the region which, when mutated had no effect on swarming motility or on EF-P semi-native gel electrophoretic mobility (Fig S3E,G,H). The *P<sub>yqhS</sub>-efp* complementation construct, however, did not restore swarming to the *efp ymfI* double mutant (Fig 2F). The failure to complement

the swarming defect of *efp ymfI* similar to that of *ymfI* alone appeared to be due a reduced level of ectopic EF-P expression relative to that of the native locus (Fig 1E), consistent with the observation that *ymfI* rescue depends on EF-P levels (Fig 6B). We conclude that transcription of *efp* from *P<sub>yqhs</sub>* is sufficient under most conditions but additional promoters may be needed to amplify expression when *ymfI* is mutated. We note that the upstream *P<sub>yqhR</sub>* may contribute to EF-P expression as transcriptomics indicates that there is no transcriptional terminator between the *yqhR* and *yqhs* genes (Fig S3F) (Nicolas et al., 2012). We conclude that, in the absence of YmfI, a threshold of EF-P protein level and thus activity is required to initiate swarming motility.

Next, the *P<sub>yqhs</sub>-efp* complementation construct was randomly mutagenized using an error prone polymerase in seven separate tubes and each PCR product was separately transformed into an *efp ymfI* double mutant background to generate seven parallel pools of transformants. Each pool of transformants was collected and spotted as a mixed population onto swarming motility agar. Cells initially grew as a tight colony in the center of the plate but, in each pool, motile cells emerged with a prolonged lag period and swarmed outward from the origin. One colony was isolated from each motile swarm and was confirmed to have restored swarming motility. Sequencing of the *P<sub>yqhs</sub>-efp* construct indicated that each isolate contained either a mutation of Lys29 to an asparagine (EF-P<sup>K29N</sup>) or a mutation of Lys32 to an arginine (EF-P<sup>K32R</sup>) (Table 1). In three swarming proficient isolates, K29N or K32R was the only mutation present (Fig 2G). Mutation of K32R was allele-specific for the rescue of swarming motility in an *efp ymfI* background as ectopic introduction of K32A was not sufficient (Fig 2H). Furthermore, neither ectopic integrant of K29N nor K32R exhibited increased protein levels relative to ectopic integrant of the wild type allele in otherwise wild type cells indicating that suppression was not simply due to increased stability or expression of the mutant proteins (Fig 1E). We conclude that particular substitutions of Lys29 and Lys32 yielded EF-P at least partially YmfI-independent and sufficient to restore swarming in the absence of YmfI.

To further characterize the YmfI-independent alleles of EF-P, each single mutant was introduced by allelic replacement at the native locus. Cells expressing EF-P<sup>K29N</sup> at the native site swarmed like the wild type and migrated as two bands on a semi-native gel (Fig 2I, Fig 1C lane 5). The majority of the EF-P<sup>K29N</sup> resolved as the lower species, unlike wild type EF-P which resolved mostly as the upper species (Fig 1C, compare lane 1 to lane 5). One way in which the ratio of upper/lower bands could be altered in this way is if EF-P<sup>K29N</sup> affected the rate of post-translational modification. To test this hypothesis, translation was inhibited in an *efp<sup>K29N</sup>* mutant and EF-P electrophoretic mobility on a semi-native gel was monitored over time. The dominant EF-P<sup>K29N</sup> lower band appeared to decrease slowly with a concomitant increase in the intensity of the upper band indicative of a slow conversion of the oxidized to reduced modification (Fig 1A, right). Further, EF-P<sup>K29N</sup> expressed from the native site was not fully independent of YmfI as mutation of *ymfI* diminished swarming migration and abolished the faint upper band in semi-native gels (Fig 1C, compare lanes 5 and 6; Fig 2I). We conclude that EF-P<sup>K29N</sup> has a decreased rate of post-translational modification thereby preventing accumulation of 5-aminopentanated EF-P.



Cells expressing EF-P<sup>K32R</sup> at the native site arrested swarming prematurely and resolved as a single band on native gels (Fig 1C lane 7; Fig 2J). Unlike *efp*<sup>K29N</sup>, mutation of *ymfI* did not diminish swarming migration of *efp*<sup>K32R</sup> or alter mobility on semi-native gel electrophoresis of the EF-P<sup>K32R</sup> protein (Fig 1C compare lanes 7 and 8; Fig 2J). Finally, wild type cells expressing the combined double mutant allele EF-P<sup>K29N,K32R</sup> exhibited a premature swarming arrest and resolved as a single band on native gels regardless of the presence of YmfI, similar to the EF-P<sup>K32R</sup> single mutant alone (Fig 1C compare lanes 9 and 10; Fig 2K). We conclude that both lysine residues contribute to the same function as the phenotype of the double mutant was not additive, and that mutation of K32R yields EF-P YmfI-independent and is epistatic to K29N.

To determine the consequence of the suppressor mutations on post-translational EF-P modification, the EF-P alleles were fused to a FLAG tag, overexpressed, purified from *B. subtilis*, and analyzed by mass spectrometry. For the wild type and EF-P<sup>K29N</sup> protein, both unmodified and 5-aminopentanylated EF-P were detected (Fig 4G–I). By contrast, only the unmodified fragment was detected for the EF-P<sup>K32R</sup> protein and no additional masses could be detected on the peptide (Fig 4J–L). We conclude that one way to bypass the need for YmfI and restore EF-P activity is to abolish EF-P modification on Lys32. We also conclude that cells mutated for *ymfI* exhibit a swarming defect because they accumulate an inhibitory 5-aminopentanone group on EF-P. Swarming inhibition may be relieved either by converting the group to 5-aminopentanol or by the accumulation of unmodified EF-P. Unmodified EF-P can accumulate by mutation of K32R, by decreasing the rate of post-translation modification as seen in K29N mutants, or by simply overexpressing EF-P protein. Finally, we conclude that, to the best of our knowledge, *B. subtilis* EF-P is the only member of its family that functions in the absence of post-translational modification.

## DISCUSSION

Elongation factor P is a highly conserved protein found in all domains of life that structurally resembles a tRNA, associates with the ribosome, and assists in translating particular primary sequences such as polyprolines (Blaha, 2009, Hanawa-Suetsugu, 2004, Schmidt, 2016, Doerfel, 2013, Ude, 2013, and Gutierrez, 2013). Furthermore, the EF-P position analogous to the site of amino acid attachment on tRNA is post-translationally modified by species-specific, structurally-divergent molecules (Lassak, 2016). Here we identify YmfI of *Bacillus subtilis* as the first protein shown to be involved in the post-translational modification of EF-P by 5-aminopentanol. YmfI is a protein of previously unknown function that is a paralog of the fatty acid biosynthesis protein FabG and requires a conserved active site residue for its function (Fig S1). Furthermore, YmfI catalyzes the NADPH-dependent alteration of EF-P electrophoretic mobility in vitro and the reduction of EF-P 5-aminopentanone to 5-aminopentanol in vivo (Fig 7A). To date, *B. subtilis* is the only species known to modify EF-P with 5-aminopentanol but YmfI homologs were found by sequence analysis and synteny with upstream genes in the Firmicutes order of Bacilliales (Fig 3A,B). Based on our analyses, we predict that the genera of *Listeria* and *Staphylococcus* also modify EF-P with 5-aminopentanol.

In *Bacillus subtilis*, EF-P is required for a flagellar-mediated form of surface motility called swarming and mutation of YmfI conferred a swarming defect. The swarming motility defect was not due to the inability to synthesize the mature 5-aminopentanol group and was rather due to the accumulation of the inhibitory oxidized 5-aminopentanone group as indicated by suppressor mutations that altered the EF-P primary sequence. One suppressor mutation changed the modified EF-P residue Lys32 to an arginine, and while the allele impaired swarming in a wild type cell, it bypassed the requirement for YmfI by abolishing modification altogether. Both a swarming impairment and lack of modification were previously reported in a site-directed mutation that changed Lys 32 to Ala (Rajkovic, 2016), but unlike the EF-P<sup>K32R</sup> allele, the EF-P<sup>K32A</sup> allele was unable to bypass the swarming requirement for YmfI. We infer that a positive charge at position 32 assists in the function of EF-P and that a lysine residue in particular is ideal in *B. subtilis*. The partial phenotypes of the EF-P K32R and K32A mutations however, indicate that 5-aminopentanylation *per se* is not explicitly required for EF-P activity. To the best of our knowledge, the EF-P protein of *B. subtilis* is the first of its kind to retain substantial biological activity in the absence of post-translational modification possibly due to the below-expected number of genomic polyprolines encoded in *B. subtilis* (Rajkovic, 2016).

Another suppressor mutation changed the highly conserved EF-P residue Lys29 to an asparagine. EF-P<sup>K29N</sup> appears to reduce the rate of 5-aminopentanylation on Lys32 as indicated by a dramatic reduction in upper EF-P band on semi-native gels. The lower band accumulated in the EF-P<sup>K29N</sup> mutant but could represent at least two different molecular species. 5-aminopentanonated EF-P resolves as the lower band as it was the only band observed in the absence of YmfI. The lower band also accumulated when EF-P was overexpressed, and unmodified EF-P predominated in mass spectrometry analyses. Thus, the lower band on semi-native gels may represent two molecular species, one in which Lys32 is unmodified and one in which Lys32 is 5-aminopentanonated. We infer that EF-P<sup>K29N</sup> restores swarming in the absence of YmfI by reducing the rate of post-translational modification thereby accumulating EF-P unmodified at Lys32. EF-P Lys29 could play a role in the catalysis of 5-aminopentanylation as a binding site for modification proteins or as a residue for allosteric regulation. While we cannot distinguish whether Lys29 is an active or allosteric site, we note that Lys29 appears to be as highly conserved as Lys32 in EF-P proteins (Fig 7B, Fig S5).

Post-translational modification is thought to be essential for EF-P activity for the organisms in which it has been studied and is generally assumed to directly participate in the synthesis of certain primary sequences, but how the modification participates in potentiating translation is unknown. If the modification does directly participate in synthesis, it seems unusual that a conserved EF-P function can tolerate a wide variety of different chemical modifications including but likely not limited to lysine, hypusine, rhamnose, and 5-aminopentanol groups depending on the organism. Furthermore, some modifications such as deoxyhypusine in the fungus *Fusarium* alter EF-P function and here we show in *B. subtilis* that 5-aminopentanonation has similar consequences, perhaps for regulatory reasons (Martinez-Rocha, 2016). Consistent with regulation, we show that in *B. subtilis* mutation of Lys32 to an Arg (a residue naturally found in other EF-P proteins; Fig 7B, Fig S5) partially preserves EF-P function in the absence of the 5-aminopentanol group. Moreover,

overexpression of EF-P and mutation of Lys29 to an asparagine results in the hyper-accumulation of unmodified EF-P and bypasses the swarming defect caused by the absence of YmfI. Thus, we hypothesize an unmodified Lys32 may be fully functional in *Bacillus subtilis*. We speculate that post-translational modification of EF-P may serve a regulatory function in *B. subtilis* and perhaps other organisms.

## Experimental Procedures

### Strains and growth conditions

*B. subtilis* and *E. coli* strains were grown in lysogeny broth (LB) (10 g tryptone, 5 g yeast extract, 5 g NaCl per L) or on LB plates fortified with 1.5% Bacto agar at 37°C. When appropriate, antibiotics were included at the following concentrations: 10 µg/ml tetracycline, 100 µg/ml spectinomycin, 5 µg/ml chloramphenicol, 5 µg/ml kanamycin, and 1 µg/ml erythromycin plus 25 µg/ml lincomycin (*mls*). Isopropyl β-D-thiogalactopyranoside (IPTG, Sigma) was added to the medium at the indicated concentration when appropriate.

For quantitative swarm assays, strains were grown to mid-log phase (OD<sub>600</sub> 0.3–1.0) concentrated to an OD<sub>600</sub> of 10 in PBS pH 7.4 (0.8% NaCl, 0.02% KCl, 100 mM Na<sub>2</sub>HPO<sub>4</sub>, and 17.5 mM KH<sub>2</sub>PO<sub>4</sub>) plus 0.5% India ink. LB plates fortified with 0.7% agar were dried for 10 min open-faced in a laminar flow hood and subsequently inoculated by spotting 10 µL cell resuspensions onto the center of the plate. Plates were dried an additional 10 min open-faced in a laminar flow hood and then incubated at 37°C in a humid chamber. Swarm radius was measured along the same axis every 30 minutes.

Images of swarm plates were obtained by toothpick-inoculating a colony into the center of an LB plate fortified with 0.7% agar. Plates were dried open-faced in a laminar flow hood for 12 min and incubated at 37°C in a humid chamber for 20 hrs. Images were taken using a BioRad Gel Doc.

### Western Blotting

Strains were grown to mid-log phase, concentrated to an OD<sub>600</sub> of 10 in lysis buffer (17.2 mM Tris pH 7.0, 8.6 mM EDTA pH 8.0, 1 mg/mL Lysozyme, 0.1 mg/mL RNaseA, 20 µg/mL DNase I, and 50 µg/mL phenylmethane sulfonyl fluoride) and incubated at 37°C for 30 min. SDS sample buffer (500 mM Tris pH 6.8, 22% glycerol, 10% SDS, and 0.12% bromophenol blue) was added, and samples were boiled for 5 min. 12 µL boiled samples were loaded onto 10% polyacrylamide native (with no added SDS) or 15% polyacrylamide denaturing (with 0.1% SDS) gels. Lysates were resolved at 150 V for 1.25 hours, transferred onto nitrocellulose membranes, and subsequently probed with a 1:40,000 dilution of anti-EF-P or a 1:80,000 dilution anti-SigA polyclonal antiserum. Following incubation with the primary antibodies, nitrocellulose membranes were probed with horseradish peroxidase conjugated goat anti-rabbit immunoglobulin G. Blots were developed using Pierce ECL substrate (Thermo Fisher Scientific). To inhibit translation, 200 µg/mL spectinomycin was added to mid-log phase cultures.

## Strain construction

All constructs were introduced into DK1042, a competent derivative of ancestral strain 3610 (Konkol et al., 2013) or laboratory strain PY79 and then transferred to the 3610 background using SPP1-mediated generalized phage transduction (Yasbin and Young, 1974). All strains used in this study are listed in Table 2. All plasmids used in this study are listed in Supplemental Table S1. All primers used in this study are listed in Supplemental Table S2.

**Complementation constructs**—To create the *efp* complementation construct, the  $P_{yqhs}$  promoter was amplified using primers 477/478 and the *efp* gene was amplified using primers 483/486 using *B. subtilis* 3610 genomic DNA as a template. Fragments were digested with EcoRI/XhoI and XhoI/BamHI respectively and subsequently ligated into the EcoRI and BamHI restriction sites of the plasmid pDG364, containing a polylinker and chloramphenicol resistance cassette between two arms of the *amyE* gene (Guérout-Fleury et al., 1996), to produce pDP85. pDP85 was transformed into DK2050 to produce DK3780. Site directed mutation of *efp* to change lysine 32 to an alanine was performed by amplifying DK3780 genomic DNA with primer pairs 3177/4039 and 3180/4038 (primers 4038 and 4039 encode the *efp*<sup>K32A</sup> mutation). The resulting fragments were subjected to Gibson assembly (Gibson, 2009), and transformed into DK2050 followed by selection for chloramphenicol resistance to produce DK2248.

To create the *ymfI* complementation construct, the  $P_{ymfF}$  promoter was amplified using primers 4724/4884 and the *ymfI* gene was amplified using primers 4721/4722 using *B. subtilis* 3610 chromosomal DNA as a template. Fragments were digested with EcoRI/HinDIII and HinDIII/NheI respectively were subsequently ligated into the EcoRI and NheI restriction sites of the plasmid pAH25, containing a polylinker and spectinomycin resistance cassette between two arms of the *amyE* gene, to produce pKRH50. pKRH50 was transformed into DK3621 followed by selection for spectinomycin resistance to produce DK3969. Site directed mutation of *ymfI* to change tyrosine 150 to an alanine was performed by amplifying DK3969 genomic DNA with primer pairs 4884/4971 and 4722/4970. The resulting fragments were subjected to Gibson assembly (Gibson, 2009) followed by PCR amplification by primers 4722/4884. The resulting DNA fragment was subsequently ligated into the EcoRI and NheI restriction sites of the plasmid pAH25 to produce pKRH67. Plasmid pKRH67 was transformed into DK3621 followed by selection on spec to produce DK4233.

Site directed mutation of the  $P_{hyspank-efp-flag}$  construct was performed by amplifying DK2448 genomic DNA (Rajkovic, 2015) with primer pairs 861/5133 and 862/5132 for *efp*<sup>K29N</sup> and 861/5143 861/5142 for *efp*<sup>K32R</sup>. Cognate fragments were subjected to Gibson assembly (Gibson, 2009) and transformed into DK2050 followed by selection for spectinomycin resistance to yield DK4246 and DK4247.

**YmfI expression construct**—To create the His-Sumo-YmfI expression construct, *ymfI* was amplified using primers 5439/5440 using *B. subtilis* 3610 chromosomal DNA as a template. The resulting fragment was digested with XhoI/SapI and subsequently ligated into the XhoI and SapI restriction sites of the plasmid pTB146 to produce pKRH76.

**Native site mutants**—Site directed mutation of *efp* at the native site was performed by allelic replacement. 3610 genomic DNA was amplified using primer pairs 4031/5133 4034/5132 for *efp*<sup>K29N</sup>, 4031/5143 4034/5042 for *efp*<sup>K32R</sup>, and 4031/5145 4034/5144 for *efp*<sup>K29N,K32R</sup>. Cognate fragments were introduced into the SmaI restriction site of pMiniMAD using Gibson assembly (Patrick and Kearns, 2008; Gibson, 2009) to produce pKRH59, pKRH60, and pKRH61 which were subsequently passed through the recA+ *Escherichia coli* strain TG1 and transformed into DK1042. Plasmid pMiniMAD (and its derivatives pKRH59, pKRH60, and pKRH61) encodes an mls resistance cassette and a temperature sensitive origin that is active at room temperature but not at 37°C. Thus, mls-resistant colonies were isolated at 37°C (ensuring integration of the plasmid into the chromosome) and subsequently grown overnight at room temperature, thereby activating the plasmid-encoded temperature sensitive origin and inciting plasmid excision. Mls-sensitive colonies were isolated and the *efp* locus was sequenced to determine the allele present at that site.

**Random mutagenesis of *efp***—Mutagenesis of the *efp* complementation construct was achieved by amplification of DK3789 genomic DNA with primer pair 4891/3180 using the error prone Taq polymerase (New England BioLabs Inc.). To decrease the frequency of obtaining mutations that increase expression of EF-P through altering its promoter, the portion of the complementation construct upstream of *efp* (including *P<sub>yqhs</sub>*) was amplified with primers 3177/4892 using the high fidelity Phusion polymerase (New England BioLabs Inc.). The two fragments were ligated together using Gibson assembly (Gibson, 2009) and the products subsequently PCR amplified with primers 954/3180. The resulting 7 pools of mutagenized *amyE::P<sub>yqhs</sub>-efp* were transformed into DK2886 and chloramphenicol-resistant colonies were selected.

Approximately 1700 colonies for each of 7 pools were scraped off of selection plates as a mixture, diluted into LB, and grown to mid-log phase at 37°C. Cell mixtures were then subjected to swarm assays as described above. Following a 9–10 hour incubation on swarm plates, swarming-competent cells began to emerge from the site of inoculation and one colony per pool was isolated from the edge of the swarm front. The *amyE::P<sub>yqhs</sub>-efp* complementation construct from each of the *ymlI* suppressors was backcrossed into DK2886 by SPP1-mediated transduction and the retention of swarming motility was confirmed. For each *ymlI* suppressor, the *efp* complementation construct was sequenced to determine the mutations present.

### Insertion/deletion mutants

***ymlF::tet***: Mutation of *ymlF* was performed by amplifying the regions upstream (with primers 4788/4789) and downstream (with primers 4790/4791) of *ymlF* using 3610 chromosomal DNA as a template, and amplifying the tetracycline resistance cassette from pDG1515 with primers 3250/3251 (Guérout-Fleury, 1995). The three fragments were ligated by Gibson assembly and transformed into DK1042 to produce DK3726. The mutation was confirmed by PCR length polymorphism analysis.

**ymfH::tet**: Mutation of *ymfH* was performed by amplifying the regions upstream (with primers 4792/4793) and downstream (with primers 4832/4795) of *ymfH* using 3610 chromosomal DNA as a template, and amplifying the tetracycline resistance cassette from pDG1515 with primers 3250/3251. The three fragments were ligated using Gibson assembly and transformed into DK1042 to produce DK3727. The mutation was confirmed by PCR length polymorphism analysis.

**ymfFH::tet**: Simultaneous mutation of *ymfF* and *ymfH* was performed by amplifying the regions upstream of *ymfF* (with primers 4788/4789) and downstream of *ymfH* (with primers 4832/4795) using 3610 chromosomal DNA as a template, and amplifying the tetracycline resistance cassette from pDG1515 with primers 3250/3251. The three fragments were ligated using Gibson assembly and transformed into DK1042 to produce DK3727. The mutation was confirmed by PCR length polymorphism analysis.

**ymfJ::tet**: Mutation of *ymfJ* was performed by amplifying the regions upstream (with primers 105/106) and downstream (with primers 107/108) of *ymfJ* using 3610 chromosomal DNA as a template, the fragments were purified and used to amplify the tetracycline resistance cassette from HaeII-digested pDG1515. The amplification product was used as a template to cement the fragment using primers 105/108. The final long-flanking homology disruption cassette (Wach, 1996) was transformed into laboratory strain PY79 and transduced to 3610 by SPP1-mediated phage transduction to produce DS236. The mutation was confirmed by PCR length polymorphism analysis.

**yqhS**: Deletion of *yqhS* was achieved through allelic replacement. 3610 genomic DNA was amplified using primer pairs 4023/4024 and 4025/4026 and the resulting fragments were introduced into the SmaI restriction site of pMiniMAD using Gibson assembly (Gibson, 2009) to produce pKRH1. Plasmid pKRH1 was passaged through the recA+ *Escherichia coli* strain TG1, transformed into DK1042, integrated by selecting mls resistant colonies at 37°C and evicted by passage at room temperature. Mls-sensitive colonies were isolated and confirmed to encode the deletion by PCR length polymorphism analysis.

**papA**: Deletion of *papA* was achieved through allelic replacement. 3610 genomic DNA was amplified using primer pairs 4027/4028 and 4029/4030 and the resulting fragments were introduced into the SmaI restriction site of pMiniMAD using Gibson assembly (Gibson, 2009) to produce pKRH2. Plasmid pKRH2 was passaged through the recA+ *Escherichia coli* strain TG1, transformed into DK1042, integrated by selecting mls resistant colonies at 37°C and evicted by passage at room temperature. Mls-sensitive colonies were isolated and confirmed to encode the deletion by PCR length polymorphism analysis.

**SPP1-mediated transduction**—SPP1-mediated transductions were performed as described previously (Yasbin, 2004). In short, lysates were created on *B. subtilis* strains grown in TY (1% Tryptone, 0.5% yeast extract, 0.5% NaCl, 10mM MgSO<sub>4</sub>, and 1mM MnSO<sub>4</sub>). Recipient strains were grown in TY to stationary phase, 1 mL diluted into 9 mL TY, and 10 µL (for tetracycline selection) or 25 µL (for spectinomycin and chloramphenicol selection) lysates were added, followed by incubation at room temperature for 30 min and selection for the respective antibiotic resistance at 37°C overnight. For transductions in

which spectinomycin or chloramphenicol-resistance was selected for, 10 mM sodium citrate was added to the selection plates.

### Mass Spectrometry

Flag-tagged EF-P was overexpressed and purified from each mutant strain (DK2448, DK3828, DK4246, and DK4247) as previously described (Rajkovic, 2016). Following purification, the eluate was concentrated and resolved on a 13% SDS-PAGE gel. Protein was visualized with colloidal Coomassie, excised from the gel, and in-gel digested with chymotrypsin. The generated peptide samples were brought up in 2% acetonitrile in 0.1% formic acid (20  $\mu$ L) and analyzed (4  $\mu$ L) by LC/ESI MS/MS with a Thermo Scientific Easy-nLC II (Thermo Scientific, Waltham, MA) coupled to a hybrid Orbitrap Elite ETD (Thermo Scientific, Waltham, MA) mass spectrometer using an instrument configuration as described (Yi et al). In-line de-salting was accomplished using a reversed-phase trap column (100  $\mu$ m  $\times$  20 mm) packed with Magic C<sub>18</sub>AQ (5- $\mu$ m 200 $\text{\AA}$  resin; Michrom Bioresources, Auburn, CA) followed by peptide separations on a reversed-phase column (75  $\mu$ m  $\times$  250 mm) packed with Magic C<sub>18</sub>AQ (5- $\mu$ m 100 $\text{\AA}$  resin; Michrom Bioresources, Auburn, CA) directly mounted on the electrospray ion source. A 40-minute gradient from 2% to 40% acetonitrile in 0.1% formic acid at a flow rate of 400 nL/minute was used for chromatographic separations. A spray voltage of 2750 V was applied to the electrospray tip and the Orbitrap Elite instrument was operated in the data-dependent mode, switching automatically between MS survey scans in the Orbitrap (AGC target value 1,000,000, resolution 120,000, and injection time 250 milliseconds) with MS/MS spectra detected in the Orbitrap (AGC target value of 50,000, 15,000 resolution and injection time 250 milliseconds). The 3 most intense ions from the Fourier-transform (FT) full scan were selected for fragmentation in the Orbitrap using ETD 100 ms activation time with supplemental CID activation with normalized collision energy of 35%. Selected ions were dynamically excluded for 10 seconds.

**Isotope Distribution Analysis**—Predicted isotope distributions were calculated using the Scientific Instrument Services, Inc. Isotope Distribution Calculator and Mass Spec Plotter. Actual abundances of each ion were quantified using Thermo Xcalibur software with a Genesis peak picking algorithm and an m/z range of 0.02. To compare the predicted and actual distributions, the measured abundances were set relative to the most abundant ion for the peptide with the indicated modification.

### Phylogenetic Analyses

All phylogenetic trees are presented using the Interactive Tree of Life visualization software (Letunic, 2016). To identify the conservation of the different EF-P post-translational modification systems and *B. subtilis* EF-P residues 29 and 32 (analogous to residues 31 and 34 respectively in *E. coli*) across all domains of life, the genomes of 191 organisms identified by Ciccarelli, *et al.* were annotated with the Pfam 29 library using the software hmmer v 3.1b2 and an E value threshold of 1e-5 (Ciccarelli, 2006; Finn, 2016; Eddy, 1998). The presence of EarP was established by the annotation of a DUF2331 domain and the presence of DHS was established by the annotation of a DS domain. The presence of EpmA was established by the annotation of a protein that contained a tRNA-synt\_2 domain with

homology beginning at residue 15–30 of the profile hidden Markov model (HMM) and without a tRNA\_anti-codon domain. The presence of YmfI was established by the presence of 3 co-oriented open reading frames separated by no more than 500 bp that encode proteins with domains found in the YmfFHI proteins. Specifically, YmfF and YmfH were identified by the presence of Peptidase\_M16 or Peptidase\_M16\_C domains, and YmfI homologs were identified by the presences of adh\_short or adh\_shortC2 domains.

To identify EF-P and eIF5a homologs, proteins that most closely aligned to the eIF-5a, EFP\_N, EFP, or Elongation-fact-P\_C were identified and subsequently aligned to the EFP\_N domain. The identity of EF-P residue 32 was determined by the residue aligning to position 30 of the EFP\_N profile HMM and the identity of EF-P residue 29 was determined by the residue aligning to position 27 of the EFP\_N profile HMM.

To gain further clarity on which bacteria are likely to encode a YmfI homolog and thereby 5-aminopentanolyated EF-P, all species taxIDs with a completed bacterial genome available on the NCBI reference sequence database were analyzed for the presence of a YmfFHI operon structure as described above.

**In vitro Reactions**—The His-Sumo-YmfI expression construct, pKRH76, was transformed into *E. coli* Rosetta gami cells and grown in Terrific broth (12 g tryptone, 24 g yeast extract, 4 mL glycerol, 2.31 g monobasic potassium phosphate and 12.54 g dibasic potassium phosphate) to mid-log phase. 1 mM IPTG was then added and the culture was grown overnight at 16°C. Cells were pelleted, resuspended in lysis buffer (50 mM Na<sub>2</sub>HPO<sub>4</sub>, 300 mM NaCl, and 10 mM imidazole) and lysed by sonication. Cell debris was pelleted by centrifugation at 31,000 × g for 30 min and Ni-nitrotriacetic acid resin (Novagen) was added to the clarified supernatant. The bead-lysate mixture was incubated at 4°C overnight. Beads were sedimented, the supernatant was removed, and the beads were washed 3 times with wash buffer (50 mM Na<sub>2</sub>HPO<sub>4</sub>, 300 mM NaCl, and 30 mM imidazole). Beads were resuspended in wash buffer, applied to a 1-cm separation column (Bio-Rad), and His-SUMO-YmfI was eluted with wash buffer containing 250 mM imidazole. To cleave the His-SUMO tag from the purified YmfI, ubiquitin ligase/protease was added and the reaction was incubated at 4°C overnight. To remove the free His-SUMO and any remaining His-SUMO-YmfI from the cleavage reaction, Ni-nitrotriacetic acid resin (Novagen) was added and incubated at 4°C for 1 hr. Beads were pelleted by centrifugation and the supernatant, containing untagged YmfI, was dialyzed into PBS pH 7.4 plus 50% glycerol and stored at 4°C. EF-P<sup>YmfI</sup>-FLAG was purified from DK3828 as described previously (RajKovic, 2016).

10 µL reactions containing 5 µg EF-P<sup>YmfI</sup>-FLAG was incubated in 100 mM sodium phosphate buffer at 37°C for 30 min. 4 µg YmfI with or without 150 µM NADPH was added to the reaction, where appropriate. Reactions were stopped by the addition of 50% glycerol, resolved by native gel electrophoresis, electroblotted, and probed with anti-EF-P polyclonal antisera.



## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This work was supported by National Science Foundation Graduate Research Fellowship Grant 1342962 to KRH, National Institutes of Health Training Grant T32 GM086252 and an OSU Center for RNA Biology Fellowship to AW, National Institutes of Health Grant GM065183 to ML, and National Institutes of Health Grant GM093030 to DBK. We thank Masaya Fujita and Winston Winkler for strains and reagents. The Fred Hutchinson Cancer Research Center Proteomics Facility is funded by Cancer Center Support Grant P30 CA015704 from the National Institutes of Health.

## References


- Balibar CJ, Iwanowicz D, Dean CR. Elongation Factor P is dispensable in *Escherichia coli* and *Pseudomonas aeruginosa*. *Curr Microbiol.* 2013; 67:293–299. [PubMed: 23591475]
- Bendezu FO, Hale CA, Bernhardt TG, de Boer PA. RodZ (YfgA) is required for proper assembly of MreB actin cytoskeleton and cell shape in *E. coli*. *EMBO J.* 2009; 28:581–590.
- Blaho G, Stanley RE, Steitz TA. Formation of the first peptide bond: the structure of EF-P bound to the 70S ribosome. *Science.* 2009; 353:966–969.
- Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. BLAST+: architecture and applications. *BMC Bioinformatics.* 2009; 10:421. [PubMed: 20003500]
- Cooper HL, Park MH, Folk JE, Safer B, Braverman R. Identification of the hypusine-containing protein Hy<sup>+</sup> as translation initiation factor eIF-4D. *Proc Natl Acad Sci.* 1983; 80:1854–1857. [PubMed: 6403941]
- Ciccarelli FD, Doerks T, von Mering C, Creevey CJ, Snel B, Bork P. Toward automatic reconstruction of a highly resolved tree of life. *Science.* 2006; 311:1283–1288. [PubMed: 16513982]
- Doerfel LK, Wohlgemuth I, Kothe C, Peske F, Urlaub H, Rodnina MV. EF-P is essential for rapid synthesis of proteins containing conservative proline residues. *Science.* 2013; 339:85–88. [PubMed: 23239624]
- Doerfel LK, Wohlgemuth I, Kubyshev V, Starosta AL, Wilson DN, Budisa N, Rodnina MV. Entropic contribution of Elongation Factor P to proline positioning at the catalytic center of the ribosome. *J Am Chem Soc.* 2015; 137:12997–13006. [PubMed: 26384033]
- Eddy SR. Profile hidden Markov models. *Bioinformatics.* 1998; 14(9):755–763. [PubMed: 9918945]
- Finn RD, Coghill P, Eberhardt RY, Eddy SR, Mistry J, Mitchell AL, et al. The Pfam protein families database: towards a more sustainable future. *Nucleic Acids Res.* 2015; 44:D279–D285. [PubMed: 26673716]
- Ganoza MC, Kiel MC, Aoki H. Evolutionary conservation of reactions in translation. *Microbiol Mol Biol Rev.* 2002; 66(3):460–485. [PubMed: 12209000]
- Gibson DG, Young L, Chuang RY, Venter JC, Hutchinson CA III, Smith HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nature Methods.* 2009; 6(5):343–345. [PubMed: 19363495]
- Guérout-Fleury AM, Shazand K, Frandsen N, Stragier P. Antibiotic-resistance cassettes for *Bacillus subtilis*. *Gene.* 1995; 167:335–336. [PubMed: 8566804]
- Guérout-Fleury AM, Frandsen N, Stragier P. Plasmids for ectopic integration in *Bacillus subtilis*. *Gene.* 1996; 180:57–61. [PubMed: 8973347]
- Gutierrez E, Shin BS, Woolstenhulme CJ, Kim JR, Saini P, Buskirk AR, Dever TE. eIF5A promotes translation of polyproline motifs. *Molec Cell.* 2013
- Hanawa-Suetsugu K, Sekine S, Sakai H, Hori-Takemoto C, Tereda T, Unzai S, et al. Crystal structure of elongation factor P from *Thermus thermophilus* HB8. *Proc Natl Acad Sci.* 2004; 101(26):9595–9600. [PubMed: 15210970]

- Inaoka T, Ochi K. Glucose uptake pathway-specific regulation of synthesis of neotrehalosdiamine, a novel autoinducer produced in *Bacillus subtilis*. *J Bacteriol.* 2007; 189(1):65–75. [PubMed: 17056753]
- Katz A, Solden L, Zou SB, Navarre WW, Ibba M. Molecular evolution of protein-RNA mimicry as a mechanism for translation control. *Nuc Acid Res.* 2013; 42:3261–3271.
- Kearns DB, Chu F, Rudner R, Losick R. Genes governing swarming in *Bacillus subtilis* and evidence for a phase variation mechanism controlling surface motility. *Mol Microbiol.* 2004; 52:357–369. [PubMed: 15066026]
- Lassak J, Keilhauer EC, Fürst M, Wuichet K, Gödeke J, Starosta AL, et al. Arginine-rhamnosylation as new strategy to activate translation elongation factor P. *Nat Chem Biol.* 2015; 11:266–270. [PubMed: 25686373]
- Lassak J, Wilson DN, Jung K. Stall no more at polyproline stretches with the translation elongation factors EF-P and IF-5A. *Mol Microbiol.* 2016; 99(2):219–235. [PubMed: 26416626]
- Letunic I, Bork P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. *Nucleic Acids Res.* 2016; 44:W242–W245. [PubMed: 27095192]
- Martinez-Rocha AL, Woriedh M, Chemnitz J, Willingmann P, Kröger C, Haderl B, et al. Posttranslational hypusination of the eukaryotic translation initiation factor-5A regulates *Fusarium graminearum* virulence. *Sci Rep.* 2016; 6:24698. [PubMed: 27098988]
- Navarre WW, Zou BS, Roy H, Xie JL, Savchenko A, Singer A, et al. PoxA, YjeK, and Elongation Factor P coordinately modulate virulence and drug resistance in *Salmonella enterica*. *Mol Cell.* 2010; 39:209–221. [PubMed: 20670890]
- Nicolas P, Mäder U, Dervyn E, Rochat T, Leduc A, Pigeonneau N, et al. Condition-dependent transcriptome reveals high-level regulatory architecture in *Bacillus subtilis*. *Science.* 2012; 335:1103–1106. [PubMed: 22383849]
- Patel HP, Costa-Mattioli M, Schulze KL, Bellen HG. The *Drosophila* deoxyhypusine hydroxylase homologue *nero* and its target eIF5A are required for cell growth and the regulation of autophagy. *J Cell Biol.* 2009; 185(7):1181–1194. [PubMed: 19546244]
- Patrick JE, Kearns DB. MinJ (YvjD) is a topological determinant of cell division in *Bacillus subtilis*. *Mol Microbiol.* 2008; 70:1166–1179. [PubMed: 18976281]
- Price AC, Zhang YM, Rock CO, White SW. Structure of  $\beta$ -Ketoacyl-[acyl carrier protein] reductase from *Escherichia coli*: negative cooperativity and its structural bias. *Biochemistry.* 2001; 40:12772–12781. [PubMed: 11669613]
- Rajkovic A, Erickson S, Witzky A, Branson OE, Seo J, Gafken PR, et al. Cyclic rhamnosylated Elongation factor P establishes antibiotic resistance in *Pseudomonas aeruginosa*. *MBio.* 2015; 6(3):e00823–15. [PubMed: 26060278]
- Rajkovic A, Hummels KR, Witzky A, Erickson S, Gafken PR, Whitelegge JP, et al. Translation Control of Swarming Proficiency in *Bacillus subtilis* by 5-Amino-pentanoylated Elongation Factor P. *J Biol Chem.* 2016; 291(21):10976–10985. [PubMed: 27002156]
- Rajkovic A, Ibba M. Elongation Factor P and the Control of Translation Elongation. *Annual Review of Microbiology.* 2017 in press.
- Sasaki K, Abid MR, Miyazaki M. Deoxyhypusine synthase gene is essential for cell viability in the yeast *Saccharomyces cerevisiae*. *FEBS Lett.* 1996; 384:151–154. [PubMed: 8612813]
- Schmidt C, Becker T, Heuer A, Braunger K, Shanmuganathan V, Pech M, et al. Structure of the hypusylated eukaryotic translation factor eIF-5A bound to the ribosome. *Nucleic Acids Res.* 2016; 44(4):1944–1951. [PubMed: 26715760]
- Schnier J, Schwelberger HG, Smit-McBride Z, Kang HA, Hershey JWB. Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast *Saccharomyces cerevisiae*. *Mol Cell Biol.* 1991; 11(6):3105–3144. [PubMed: 1903841]
- Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics.* 2014; 30(9):1312–1313. [PubMed: 24451623]
- Ude S, Lassak J, Starosta AL, Kraxenberger T, Wilson DN, Jung K. Translation elongation factor EF-P alleviates ribosome stalling at polyproline stretches. *Science.* 2013; 339:82–85. [PubMed: 23239623]

- Wach A. PCR-synthesis of marker cassettes with long flanking homology regions for gene disruptions in *S. cerevisiae*. *Yeast*. 1996; 12:259–265. [PubMed: 8904338]
- Yanagisawa T, Sumida T, Ishii R, Takemoto C, Yokoyama S. A paralog of lysyl-tRNA synthetase aminoacylates a conserved lysine residue in translation elongation factor P. *Nat Struct Mol Bio*. 2010; 17(9):1136–1143. [PubMed: 20729861]
- Yanagisawa T, Takahashi H, Suzuki T, Masuda A, Dohmae N, Yokoyama S. *Neisseria meningitidis* translation elongation factor P and its active-site arginine residue are essential for cell viability. *PLoS One*. 2016; 11(2):e0147907. [PubMed: 26840407]
- Yasbin RE, Young FE. Transduction in *Bacillus subtilis* by bacteriophage SPP1. *J Virol*. 1974; 14:1343–1348. [PubMed: 4214946]
- Yi EC, Lee H, Aebersold R, Goodlett DR. A microcapillary trap cartridge-microcapillary high-performance liquid chromatography electrospray ionization emitter device capable of peptide tandem mass spectrometry at the attomole level on an ion trap mass spectrometer with automated routine operation. *Rapid Commun Mass Spectrom*. 2003; 17:2093–8. [PubMed: 12955739]


### SUMMARY

Elongation factor P (EF-P) is found in all living things and helps ribosomes translate proline rich sequences. Moreover, EF-P is modified with different chemical groups depending on the organism and modification is thought to be essential for activity. Here we find the first protein, YmfI, involved in modification of *B. subtilis* EF-P with 5-aminopentanol and show that, in the absence of YmfI, an inhibitory intermediate accumulates. Further, we show that EF-P biological activity can be restored to cells lacking YmfI by specific mutations that reduce or abolish modification, suggesting that the presence of the modification may be regulatory. Phylogenetic analysis suggests that EF-P may be similarly modified in *Listeria* and *Staphylococcus*.



**Figure 1. EF-P resolves as two species on a semi-native gel in a YmfI-dependent manner**  
 (A) Translation was inhibited in mid-log phase cultures by the addition of spectinomycin, lysates were subsequently harvested at the indicated time points, resolved by semi-native (top panel, “SN”) or denaturing (middle and bottom panels) polyacrylamide gel electrophoresis, electroblotted, and probed with anti-EF-P or anti-SigA polyclonal antisera (used as a loading control) as indicated. The following strains were used to generate the samples: wild type (DK1042), *ymfI* (DK3621), and *efp<sup>K29N</sup>* (DK4282). For denaturing gels, EF-P resolved at approximately 22 kDa and SigA resolved at approximately 46 kDa. The black arrow indicates the upper band and the white arrow indicates the lower band. (B) Lysates of mid-log phase cultures were resolved by semi-native (top panel, “SN”) or denaturing (middle and bottom panels) polyacrylamide gel electrophoresis, electroblotted, and probed with anti-EF-P or anti-SigA polyclonal antisera as indicated. The following strains were used to generate the samples: wild type (3610), *cheC* (DS1045), *cheD* (DS1064), *comP* (DS1028), *efp* (DS1124), *flhG* (DS1164), *rnmB*-16S (DS1146), *srfAA* (DS1102), *srfAB* (DS1044), *srfAC* (DS1122), *swrA* (DS1026), *swrB* (DS1107), *swrC* (DS1113), *yabR* (DS1078), and *ymfI* (DS1029) (C) Lysates of mid-log phase cultures were resolved by semi-native (top panel, “SN”) or denaturing (middle and bottom panels)

polyacrylamide gel electrophoresis, electroblotted, and probed with anti-EF-P or anti-SigA polyclonal antisera as indicated. Lanes are numbered at the bottom of the panels for clarity in text. The presence and absence of a wild type copy of the *ymfI* gene is indicated by (+) and (-) respectively at the top of the panels. The following strains were used to generate samples: wild type (DK1042), *ymfI* (DK3621), *efp*<sup>K32A</sup> (DK3235), *efp*<sup>K32A</sup> *ymfI* (DK3712), *efp*<sup>K29N</sup> (DK4282), *efp*<sup>K29N</sup> *ymfI* (DK4396), *efp*<sup>K32R</sup> (DK4359), *efp*<sup>K32R</sup> *ymfI* (DK4397), *efp*<sup>K29N,K32R</sup> (DK4420), and *efp*<sup>K32A,K32R</sup> *ymfI* (DK4436). (D) EF-P-FLAG purified from a *ymfI* mutant (EF-P-FLAG<sup>*ymfI*</sup>) was incubated alone, with YmfI, or with YmfI and 150 mM NADPH for 30 min at 37C. Reactions were subsequently resolved by semi-native gel electrophoresis, electroblotted, and probed with anti-EF-P antisera. (E) Lysates of mid-log phase cultures were resolved by semi-native (top panel, “SN”) or denaturing (middle and bottom panels) polyacrylamide gel electrophoresis, electroblotted, and probed with anti-EF-P or anti-SigA polyclonal antisera as indicated. The following strains were used to generate the samples: wild type (DK1042), *efp* (*efp*) (DK3780), *ymfI* *efp* (*efp*) (DK3789), *efp*<sup>K32A</sup> (DK3235), *efp* (*efp*<sup>K32A</sup>) (DK2248), *efp*<sup>K29N</sup> (DK4282), *efp* (*efp*<sup>K29N</sup>) (DK4043), *efp*<sup>K32R</sup> (DK4359), *efp* (*efp*<sup>K32R</sup>) (DK4072).




**Figure 2. Cells mutated for *ymfl* are defective in swarming motility and swarming can be restored by mutations in *efp***


(A) Top views of centrally-inoculated swarm plates incubated overnight at 37°C were imaged against a black background. Zones of colonization appear light grey. The plate inoculated with the *ymfl* mutant has internal rings that mark the locations at which the population stopped moving and restarted at a later time point. Note: a comparable cessation can be seen at hour 5 in the quantitative swarm expansion assay in panel 2B. The following strains were used to generate the panels: wild type (DK1042), *efp* (DK2050), *ymfl* (DK3621), *efp*<sup>K32A</sup> (DK3235), and *ymfl efp*<sup>K32A</sup> (DK3712). (B-K) Quantitative swarm expansion assays in which mid-log phase cultures were concentrated and used to inoculate swarm plates. Swarm expansion was monitored along the same axis every 30 min for 5–6

hours. Each data point represents the average of three replicates and error bars represent the standard deviation. The following strains were used as the inoculum (B) wild type (DK1042), *efp* (DK2050), and *ymfI* (DK3621). (C) *efp*<sup>K32A</sup> (DK3235) and *efp*<sup>K32A</sup> *ymfI* (DK3712). (D) *ymfI* (*ymfI*<sup>Y150A</sup>) (DK4233), *ymfI* (*ymfI*) (DK3969), and *ymfI* (DK3621). (E) *efp* (DK2050) and *efp* (*efp*) (DK3780). (F) *efp ymfI* (DK2886), and *efp ymfI* (*efp*) (DK3789). (G) *efp ymfI* (*efp*) DK3789, *efp ymfI* (*efp*<sup>K29N</sup>) (DK4043), and, *efp ymfI* (*efp*<sup>K32R</sup>) (DK4072). (H) *efp ymfI* (*efp*) (DK3789) and *efp ymfI* (*efp*<sup>K32A</sup>) (DK2889). (I) *efp*<sup>K29N</sup> (DK4282), *efp*<sup>K29N</sup> *ymfI* (DK4396), and *ymfI* (DK3621). (J) *efp*<sup>K32R</sup> (DK4359), *efp*<sup>K32R</sup> *ymfI* (DK4397), and *ymfI* (DK3621). (K) *efp*<sup>K29N,K32R</sup> (DK4420), *efp*<sup>K29N,K32R</sup> *ymfI* (DK4436), and *ymfI* (DK3621).






**Figure 3. Genetic architecture and phylogenetic distribution of the *ymfI* locus**  
 (A) Predicted genetic architecture of the *ymfI* locus and the design of the  $P_{ymfF}$ -*ymfI* complementation construct. Both *ymfF* and *ymfH* are predicted to encode peptidases and *ymfJ* encodes a DUF3235-domain containing protein. (B) The distribution of homologs of the EF-P modification enzymes deoxyhypusine synthase, DHS (dark blue), EpmA (light blue), EarP (yellow), and YmfI (red) across the three domains of life. YmfI is a member of the large family of alcohol dehydrogenases and the proximity to neighboring genes as indicated in Fig 3A was used to aid in the identification of YmfI homologs. Where multiple enzymes are encoded in the same genome, the bar is split accordingly. White space indicates the absence of a homolog to any EF-P modification enzyme. Numbers indicate the following clades (1) Flavobacterium-Cytophaga-Bacteroides group, (2) Chlamydiales, (3) Planctomycetes, (4) Spirochaetes, (5) Actinobacteria, (6) Deinococcus-Thermus group, and (7) Cyanobacteria. *Bacillus subtilis* is highlighted in pink. See Fig S5 enlarged map with species names. Table S3 contains the accession numbers for each species and Table S4 contains all sequences called to be YmfI in all completed bacterial genomes to date.



**Figure 4. Deletion of *ymfI* results in 5-aminopentanone of EF-P and can be suppressed by abolishing EF-P post-translational modification**


Extracted ion chromatograms of chymotrypsin-digested EF-P peptide from wild type (A–C), *ymfI* mutant (D–F), *efp*<sup>K29N</sup> mutant (G–I), and *efp*<sup>K32R</sup> mutant (J–L). Three different species were detected for the peptide corresponding to the wild type sequence QHVKPGKGAAF containing including unmodified (A,D,G,J), 5-aminopentanolylated (B,E,H,K), and 5-aminopentanone (C,F,I,L) lysine residue 32. All chromatograms for *ymfI* represent the 2+ ion for the indicated peptide. All other chromatograms represent the 3+ ion for the indicated peptide. Point mutations are indicated in bold red lettering.

Predicted chemical structures are indicated. The cartoon indicates that the hydroxyl/carbonyl group is at the C3 position but it is possible that the hydroxyl group is at the C4 position instead. The precise position of the carbonyl can only be unequivocally determined with the use NMR or other high resolution structural methods.



**Figure 5. EF-P is 5-aminopentanoned in the absence of YmfI**

MS2 spectrum generated from ETD fragmentation of the QHVKPGKGAAF peptide. Both (A) Unmodified (precursor m/z of 570.320) and (B) 5-aminopentanoned (precursor m/z of 413.752) peptide were detected in the absence of *ymfI*. z ions are indicated in blue, and c ions are indicated in green. Site of 5-aminopentanonation (Lys32) is marked in red.



**Figure 6. Overexpression of EF-P results in hyper-accumulation of the unmodified form and partially bypasses the need for YmfI**

A) An *efp* mutant and B) a *efp ymfI* double mutant each with an ectopically integrated  $P_{\text{hyspank}}$ -EF-P-FLAG construct was induced with the indicated concentrations of IPTG and measured for swarming motility radius after 4 hours of incubation (upper panel) and Western blot analysis following semi-native gel (SN) (top row) and denaturing (middle and bottom rows) electrophoresis of cell lysates (lower panel). Note, dashed line on 4 hr swarm expansion graph indicates the extent of expansion of either wild type (A) or a *ymfI* mutant (B). The following strains were used to generate samples: *efp P<sub>hyspank</sub>-efp-flag* (DK2448) and *efp ymfI P<sub>hyspank</sub>-efp-flag* (DK3828). Wild type (DK1042) and *ymfI* (DK3621) were used to generate the dashed lines.



**Table 1**Mutations in *efp* that improve swarming in the absence of YmfI

Strain Number	Genotype	Nucleotide substitution(s)
DK4043	<i>efp</i> <sup>K29N</sup>	AAA > AAT (residue 29)
DK4978	<i>efp</i> <sup>K29N</sup>	AAA > AAT (residue 29)
DK4072	<i>efp</i> <sup>K32R</sup>	AAA > AGG (residue 32)
DK4075	<i>efp</i> <sup>K32R,E101V</sup>	AAA > AGA (residue 32) GAA > GTA (residue 101)
DK4076	<i>efp</i> <sup>K32R,V111M</sup>	AAA > AGA (residue 32) GTG > ATG (residue 111)
DK4073	<i>efp</i> <sup>K32R,E124G</sup>	AAA > AGA (residue 32) GAA > GGA (residue 124)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2

## Strains

Strain	Genotype	Reference
3610	Wild type	
DK1042	<i>comJ<sup>Q12L</sup></i>	Konkol, 2013
DK1962	<i>comJ<sup>Q12L</sup> yqhS</i>	
DK2050	<i>comJ<sup>Q12L</sup> efp</i>	Rajkovic, 2016
DK2248	<i>comJ<sup>Q12L</sup> efp amyE::P<sub>yqhS</sub>-efp<sup>K32A</sup> cat</i>	
DK2448	<i>comJ<sup>Q12L</sup> efp amyE::P<sub>hyspank</sub>-efp-flag spec</i>	Rajkovic, 2016
DK2886	<i>comJ<sup>Q12L</sup> efp ymfI::tet</i>	
DK2889	<i>comJ<sup>Q12L</sup> efp ymfI::tet amyE::P<sub>yqhS</sub>-efp<sup>K32A</sup> cat</i>	
DK3159	<i>comJ<sup>Q12L</sup> papA</i>	
DK3235	<i>comJ<sup>Q12L</sup> efp<sup>K32A</sup></i>	Rajkovic, 2016
DK3621	<i>comJ<sup>Q12L</sup> ymfI::tet</i>	
DK3712	<i>comJ<sup>Q12L</sup> efp<sup>K32A</sup> ymfI::tet</i>	
DK3726	<i>comJ<sup>Q12L</sup> ymfF::tet</i>	
DK3727	<i>comJ<sup>Q12L</sup> ymfH::tet</i>	
DK3728	<i>comJ<sup>Q12L</sup> ymfFH::tet</i>	
DK3780	<i>comJ<sup>Q12L</sup> efp amyE::P<sub>yqhS</sub>-efp cat</i>	
DK3789	<i>comJ<sup>Q12L</sup> efp ymfI::tet amyE::P<sub>yqhS</sub>-efp cat</i>	
DK3828	<i>comJ<sup>Q12L</sup> efp ymfI::tet amyE::P<sub>hyspank</sub>-efp-flag spec</i>	
DK3969	<i>comJ<sup>Q12L</sup> ymfI::tet amyE::P<sub>ymfF</sub>-ymfI spec</i>	
DK4043	<i>comJ<sup>Q12L</sup> efp ymfI::tet amyE::P<sub>yqhS</sub>-efp<sup>K29N</sup> cat</i>	
DK4072	<i>comJ<sup>Q12L</sup> efp ymfI::tet amyE::P<sub>yqhS</sub>-efp<sup>K32R</sup> cat</i>	
DK4073	<i>comJ<sup>Q12L</sup> efp ymfI::tet amyE::P<sub>yqhS</sub>-efp<sup>K32R,E124G</sup> cat</i>	
DK4075	<i>comJ<sup>Q12L</sup> efp ymfI::tet amyE::P<sub>yqhS</sub>-efp<sup>K32R,E101V</sup> cat</i>	
DK4076	<i>comJ<sup>Q12L</sup> efp ymfI::tet amyE::P<sub>yqhS</sub>-efp<sup>K32R,V111M</sup> cat</i>	
DK4233	<i>comJ<sup>Q12L</sup> ymfI::tet amyE::P<sub>ymfF</sub>-ymfI<sup>Y150A</sup> spec</i>	
DK4246	<i>comJ<sup>Q12L</sup> efp amyE::P<sub>hyspank</sub>-efp<sup>K29N</sup>-flag spec</i>	
DK4247	<i>comJ<sup>Q12L</sup> efp amyE::P<sub>hyspank</sub>-efp<sup>K32R</sup>-flag spec</i>	
DK4282	<i>comJ<sup>Q12L</sup> efp<sup>K29N</sup></i>	
DK4359	<i>comJ<sup>Q12L</sup> efp<sup>K32R</sup></i>	
DK4396	<i>comJ<sup>Q12L</sup> efp<sup>K29N</sup> ymfI::tet</i>	
DK4397	<i>comJ<sup>Q12L</sup> efp<sup>K32R</sup> ymfI::tet</i>	
DK4420	<i>comJ<sup>Q12L</sup> efp<sup>K29N,K32R</sup></i>	
DK4436	<i>comJ<sup>Q12L</sup> efp<sup>K29N,K32R</sup> ymfI::tet</i>	
DS235	<i>ymfI::tet</i>	Kearns, 2004
DS236	<i>ymfJ::tet</i>	
DS1026	<i>swrA::Tn10 spec</i>	Kearns, 2004

Strain	Genotype	Reference
DS1028	<i>comP::Tn10spec</i>	Kearns, 2004
DS1029	<i>ymfI::Tn10spec</i>	Kearns, 2004
DS1044	<i>srfAB::Tn10spec</i>	Kearns, 2004
DS1045	<i>cheC::Tn10spec</i>	Kearns, 2004
DS1064	<i>cheD::Tn10spec</i>	Kearns, 2004
DS1078	<i>yabR::Tn10spec</i>	Kearns, 2004
DS1102	<i>srfAA::Tn10spec</i>	Kearns, 2004
DS1107	<i>swrB::Tn10spec</i>	Kearns, 2004
DS1113	<i>swrC::Tn10spec</i>	Kearns, 2004
DS1122	<i>srfAC::Tn10spec</i>	Kearns, 2004
DS1124	<i>efp::Tn10spec</i>	Kearns, 2004
DS1146	<i>rrnB::Tn10spec</i>	Kearns, 2004
DS1164	<i>flhG::Tn10spec</i>	Kearns, 2004
PY79	<i>sfp<sup>0</sup> swrA</i>	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript